Medicago receives FDA clearance to initiate influenza vaccine trial
The Phase I trial will be followed by a Phase IIa trial for the seasonal trivalent vaccine with the recommended H1N1, H3N2 and B influenza strains, which the
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.
Circassia said PAP-1, a novel topical therapeutic for psoriasis and atopic dermatitis, is a highly specific immunosuppressant and a selective Kv1.3 inhibitor that has ideal topical delivery characteristics.